Biotransformation of cerivastatin in mice, rats, and dogs in vivo

Drug Metabolism and Disposition

Volumn 26, Issue 7, 1998, Pages 640-652

  Boberg, Michael ^a   Angerbauer, Rolf ^b   Kanhai, Wolfgang K ^b   Karl, Wolfgang ^b   Kern, Armin ^b   Radtke, Martin ^b   Steinke, Wolfram ^b  

^a BAYER AG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DEMETHYLATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG LABELING; DRUG OXIDATION; DRUG TRANSFORMATION; HYPERCHOLESTEROLEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOTRANSFORMATION; DEALKYLATION; DOGS; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MICE; OXIDATION-REDUCTION; PYRIDINES; RATS; RATS, WISTAR; SPECIES SPECIFICITY;

EID: 0031843611     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Angerbauer R, Bischoff H, Steinke W and Ritter W (1994) BAY w 6228. Drugs Fut 19:537-541.
2. Angerbauer R, Fey P, Huebsch W, Philipps T, Bischoff H, Petzinna D, Schmidt D and Thomas G (1993) Substituted pyridyl-dihydroxy-heptenoic acid and its salts. U.S. Patent 5,177,080.
3. Berry MN and Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells. J Cell Biol 43:506-510.
4. Bischoff H and Petzinna D (1992) BAY w 6228: a new generation HMG-CoA reductase inhibitor II. Inhibition of cholesterol synthesis in rats and dogs. XI International Symposium on Drugs Affecting Lipid Metabolism, Florence, May 13-16, 1992, Abstracts, p. 69.
5. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J and Radtke M (1997) Metabolism of cerivastatin by human liver microsomes in vitro: characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25:321-331.
6. Corsini A, Arnaboldi L, Raitieri M, Quarato P, Faggiotto A, Paoletti R and Fumagalli R (1996) Effect of the new HMG-CoA reductase inhibitor BAY w 6228 on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharm Res 33:55-61.
7. Dain JG, Fu E, Gorski J, Nicoletti J and Scallen TJ (1993) Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 21:567-572.
8. Duggan DE and Vickers S (1990) Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev 22:333-362.
9. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY and Weinstein SH (1991) Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 19:740-748.
10. Faed EM (1984) Properties of acyl glucuronides, implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 15:1213-1249.
11. Grob K and Grob K Jr (1974) Isothermal analysis on capillary columns without stream splitting: role of the solvent. J Chromotogr 94:53-64.
12. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB and Duggan DE (1993) Biotransformation of lovastatin V: species differences in in vitro metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos 21:1003-1011.
13. 14C-radiolabelled pesticides. J Planar Chromatogr 6:368-371.
14. Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E and Tanaka M (1992) Disposition and metabolism of pravastatin sodium in rats, dogs, and monkeys. Europ J Drug Metab Pharmacokin 17:103-113.
15. Michniewicz BM, Black AE, Sinz MW and Woolf TF (1994) In vitro and in vivo metabolism of atorvastatin (CI-981). Proceedings of the Sixth North American ISSX Meeting, Raleigh, NC, Oct. 23-27, 1994, p 93, International Society for the Study of Xenobiotics, Bethesda, Maryland.
16. Moldeus P, Hoeberg J and Orrenius S (1978) Isolation and use of liver cells. Methods Enzymol 52:60-71.
17. Petersson G (1970) Mass spectrometry of aldonic and deoxyaldonic acids as trimethylsilyl derivatives. Tetrahedron 26:3413-3428.
18. Steinke W, Yamashita S, Tabei M, Ahr HJ, Beckermann B, Domdey-Bette A, Goeller G, Schwarz T and Siefert HM (1996) Cerivastatin, a new inhibitor of HMG-CoA reductase: pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 24(suppl 9):7-27.
19. Tang B-K (1990) Drug glucosidation. Pharmac Ther 46:53-56.
20. Tse FLS, Smith HT, Ballard FH and Nicoletti J (1990) Disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in mouse, rat, dog, and monkey. Biopharm Drug Dispos 11:519-531.
21. Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G and Duggan DE (1990) In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG-CoA reductase. Drug Metab Dispos 18:476-483.